step-by-step healthcare SEO strategy<\/a> covers search routes that need no ad approval.<\/p>\nHow to check a product or account against the EDA lists<\/h2>\n
Open the EDA’s two advertising-violation pages, one for registered and one for unregistered products, and search them for the product or account name. Each row gives the venue, the material type, the advertising date and the EDA’s status label, and most notice codes link to a PDF notice. You do not need an account to read them.<\/p>\n
Read the status column with care. On 4 October 2026 the registered list showed 19 notices as active and 4 as inactive, and all 20 unregistered notices were active. We do not interpret the label beyond what the EDA prints, and the EDA itself calls the notices regulatory assessments, not court rulings.<\/p>\n
The lists only show what the EDA has acted on. A competitor ad that is not listed has not been cleared; it just has not been flagged. If you find one making claims you believe are unapproved, screenshot it, copy the link and note the date. Then report it on 15301 or through EDA’s official channels, not only through a platform’s report button.<\/p>\n
Our read<\/h2>\n
Egypt’s public lists change who carries the risk. The EDA records the account that ran the ad, so a doctor, pharmacist or influencer who reads an unapproved script now has their name on a government page. Brands that brief creators loosely are passing that exposure to the people they pay.<\/p>\n
Our position is that the regulator’s approval reference should travel with every asset: in the brief, in the contract and in the file name. It costs one field in a brief and one line in a contract.<\/p>\n
We also think “registered” is the most dangerous word in a health marketing meeting. All 23 notices on the registered list involve products the EDA had already registered. Registration answers whether a product can be sold. It says nothing about whether this caption, from this account, can run.<\/p>\n
The unregistered list points at weight-loss injectables. Seven of its 20 notices concern GLP-1-type products, and two of those were shown at a medical conference, a venue few compliance teams monitor. Clinics and diet brands selling these products should assume the regulator is watching.<\/p>\n
The weak point in our analysis is classification. Product categories on the unregistered list are our grouping, not the EDA’s, and both lists grow as the EDA adds notices. These counts describe the pages as we read them on 4 October 2026.<\/p>\n
FAQ<\/h2>\nCan I advertise a registered medicine on Facebook in Egypt without EDA approval?<\/h3>\n
No. The EDA keeps a separate violations list for exactly this case, headed “Unapproved Advertisement For A Product Registered With The Egyptian Drug Authority”. On 4 October 2026 it held 23 notices, 13 of them for Facebook ads. Registration lets you sell a product. It does not approve any ad for it.<\/p>\n
An influencer posted about our product without asking us. Are we liable?<\/h3>\n
We cannot answer liability for you, and the EDA lists do not show how fault is split. What they do show: notices record the advertising entity, which on the registered list is most often a doctor, a doctor-branded page or an influencer. Send a written takedown request, keep the evidence, and tell the regulator about claims you never approved.<\/p>\n
Which products does the EDA flag most often in its unregistered-product notices?<\/h3>\n
GLP-1-type weight-loss injectables. By our classification they account for 7 of the 20 unregistered-product notices the EDA listed on 4 October 2026, and 2 of those were shown at a medical conference. Bodybuilding hormones and peptides account for 4 notices, NAD+ or mesotherapy-type injectables for another 4, and patches, gels and herbal products for the rest.<\/p>\n
Does an EDA advertising notice mean the advertiser broke the law?<\/h3>\n
Not on its own. According to Egyptian Streets, the EDA says its notices reflect its regulatory assessment based on information available at publication and are not judicial rulings. Each notice also carries a status the EDA labels active or inactive. Treat a listing as a serious regulatory warning, and take legal advice on any consequences.<\/p>\n
How do I report a medicine ad I think breaks the rules?<\/h3>\n
In Egypt, call the EDA hotline 15301 or use its official reporting channels; the authority says reports are handled confidentially. In Saudi Arabia, the SFDA asks people to report advertising violations on its unified number 19999. Screenshot the post, copy its link and note the date first, because a deleted post leaves you with no evidence.<\/p>\n
Where this leaves your next campaign<\/h2>\n
Whether medicine ads are allowed on social media in Arab markets is the wrong thing to ask. In Saudi Arabia, non-prescription medicines can run with SFDA approval, and Egypt’s lists show that approval is the test the EDA applies. What matters is whether you can show the approval for the exact words a specific account published, on the day it went live.<\/p>\n
If you hold a regulator approval for every asset and a signed script for every creator, launch, and check the EDA lists for your category every month. If you do not, fix the approval trail first, starting with doctors and creators, because they are who Egypt’s registered list names most often. For a Saudi example of growth through organic search instead, see the Delta Medical Labs case study<\/a>.<\/p>\nWant a second pair of eyes on your approval trail? Talk to me about my health brand’s ad plan<\/a>.<\/p>\n